Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Mouth Neoplasms 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Vaccinia 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

Bevacizumab 19Paclitaxel 16Carboplatin 12pembrolizumab 11liposomal doxorubicin 10Cyclophosphamide 9Specimen Handling 8Gemcitabine 8olaparib 7fludarabine 7Topotecan 7Magnetic Resonance Spectroscopy 7Taxes 5Immunoglobulin G 5Fulvestrant 5Disulfides 5niraparib 4Oxaliplatin 4Nivolumab 4Biopsy 4trastuzumab deruxtecan 3palbociclib 3mirvetuximab soravtansine 3aldesleukin 3Leucovorin 3Fluorouracil 31-dodecylpyridoxal 3ulixertinib 2nilotinib 2ipatasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × cemiplimab × 30 days × Clear all
NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡